The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > EMA Phasing Out Follow-Up Measures

EMA Phasing Out Follow-Up Measures

Posted 02 August 2012 | By Louise Zornoza

The European Medicines Agency (EMA) is phasing out so-called "follow-up measures" for human drugs requiring post-marketing studies this month, instead replacing them with three categories of post-marketing commitments:

  • Conditions in Annex II (obligations or specific obligations to fulfil post-authorization measures);
  • Additional pharmacovigilance activities in the risk-management plan;
  • Recommendations for further development.

The old "follow-up measures" established studies and other activities that the European Medicines Agency and the Committee for Human Medicinal Products had asked the marketing authorization holder to perform.

This new system of classification is being implemented in stages. The first phase tackled initial marketing-authorization-application opinions as of June 2011, followed by post-authorization procedures starting in November 2011. Companies affected by the new classification changes will receive an outcome fax for each applicable product that will include information about the new classification of follow-up measures, together with any actions that they need to take.

Read more:

EMA - European Medicines Agency phasing out follow-up measures

Read more Breaking News from RegLink


© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.